Introduction {#s01}
============

The gastrointestinal epithelium depends on precise regulation of the Wnt signaling pathway to coordinate stem cell maintenance, proliferation, and cell lineage differentiation ([@bib9]). During homeostasis, the stem cell niche confines Wnt activity to the crypt compartment by limiting the availability of Wnt ligands ([@bib53]; [@bib18]; [@bib64]), R-spondin coactivators, and BMP antagonists ([@bib28]; [@bib2]; [@bib61]). Binding of Wnt to Frizzled receptors and LRP5/6 coreceptors results in β-catenin (CTNNB1) stabilization, nuclear import, and transcriptional activation of Wnt target genes. In the absence of Wnt ligands, the cytoplasmic destruction complex that contains Adenoma polyposis coli (APC), AXIN1/2, the serine/threonine kinases GSK3B, and CSNK1A1 mediates CTNNB1 phosphorylation, ubiquitinylation, and proteasomal degradation ([@bib58]). Several mutations have been identified that result in ligand-independent CTNNB1 stabilization in cancers ([@bib71]). In colorectal cancer (CRC), truncating *APC* mutations are most frequent and can be found in ∼80% of all patients ([@bib7]). Homozygous *APC* loss causes adenoma-like growth, which is considered as a precursor lesion that can further progress into carcinoma by acquisition of additional driver mutations ([@bib70]).

Molecular characterization has led to the identification of a conserved transcriptional Wnt signature that is shared between cultured cell lines ([@bib66]; [@bib65]) and intestinal stem cells in mouse ([@bib41]) and human ([@bib26]). Wnt-responsive genes such as *LGR5*, *EPHB2*, *TNFRSF19*, and *PTK7* have subsequently been identified as specific markers of actively cycling gastrointestinal stem cells ([@bib4]; [@bib26], [@bib27]; [@bib59]). Interestingly, mouse *Apc* mutant adenomas ([@bib51]), as well as human CRC ([@bib69]; [@bib39]) are also characterized by induction of a Wnt/Stem cell signature, emphasizing the progenitor status of normal crypts and tumors. The presence of functional stem cells has been described in mouse adenomas ([@bib54]; [@bib33]) and in xenotransplanted CRC cells ([@bib10]; [@bib57]), indicating a hierarchical organization of tumors despite constitutive Wnt activation.

Pronounced transcriptional Wnt activity has been associated with a tumor subtype with favorable prognosis ([@bib13]; [@bib21]). Recent experiments, however, have shown that progressed CRC cells remain addicted to Wnt activity ([@bib15]; [@bib44]), providing a rationale for therapeutic targeting. While pharmacological strategies are available to interfere with upstream pathway mutations ([@bib22]; [@bib32]; [@bib60]), only limited options exist for the majority of tumors that are driven by *APC* mutations ([@bib43]). In preclinical models, global interference with Wnt signaling resulted in gastrointestinal toxicity ([@bib34]; [@bib28]), emphasizing a demand for strategies that do not interfere with homeostatic signaling. *APC* mutant cells undergo extensive pathway rewiring ([@bib5]), which could create new vulnerabilities. Specific dependence of mouse adenomas has been described on Stat3 ([@bib47]), mTORC1 ([@bib17]), Yap/Taz ([@bib3]), Rac1 ([@bib42]), or the ER stress regulator Grp78 ([@bib68]).

Despite these promising examples, a systematic characterization of normal and oncogenic Wnt has not been performed yet. Here we have set out to catalog the physiological and oncogenic Wnt responses in primary human colon epithelial cells on the transcriptome and proteome level. We take advantage of the organoid culture model that allows expansion of normal and tumor gastrointestinal epithelia ([@bib52]) and genetic engineering of oncogenic mutations by CRISPR/Cas9 technology ([@bib55]; [@bib16]; [@bib38]). By subjecting normal and *APC* mutant isogenic organoid lines to Wnt-stimulation, we aimed to generate an expression resource for stratification of extrinsic and intrinsic Wnt responses.

Results {#s02}
=======

Differential analysis of Wnt-receptor-- and *APC*-KO--induced signaling in human colon organoids {#s03}
------------------------------------------------------------------------------------------------

To distinguish receptor-induced from constitutive Wnt pathway activation, we have introduced truncating *APC* mutations within the mutation cluster region by the CRISPR/Cas9 technology in normal human colon organoids ([Fig. 1 A](#fig1){ref-type="fig"}). The cells were derived from nonpathological mucosa of three separate subjects to account for differences in gender, age, and location (Fig. S1 A). Growth independence from Wnt/R-spondin served as a stringent selection criterion for successful targeting of *APC*, the resulting organoids (*APC*-KO) were clonally expanded, and the introduced mutations were confirmed by Sanger sequencing and Western blot (WB) analysis (Fig. S1, B and C). By culturing WT and *APC*-KO organoids in Wnt/R-spondin--containing and deprived medium, we defined four biological conditions for differential analysis ([Fig. 1 B](#fig1){ref-type="fig"}): receptor-mediated, "extrinsic" stimulation was measured in WT cells ± Wnt/R-spondin. To address the "intrinsic" effect of *APC*-KO, both genotypes were compared in the presence of Wnt/R-spondin to normalize for the physiological stimulation. Comparison of *APC*-KO ± Wnt/R-spondin allowed us to study signal responsiveness in presence of constitutive activation, and comparison of both genotypes in the absence of Wnt/R-spondin represents the combination of extrinsic and intrinsic stimulation. 2 d after Wnt/R-spondin withdrawal, all WT lines showed a compact morphology indicative of cellular differentiation ([Fig. 1 C](#fig1){ref-type="fig"}). By quantitative RT-PCR (qRT-PCR), we observed robust induction of differentiation markers (*FABP1*, *KRT20*, *TFF1*, and *CA2*) and reduction of Wnt/Stem cell markers (*AXIN2*, *LGR5*, *ASCL2*, and *SMOC2*; [Fig. 1 D](#fig1){ref-type="fig"}), confirming responsiveness of our models.

![**Differential profiling of receptor-induced and constitutive Wnt signaling. (A)** Experimental approach for molecular profiling of CRISPR/Cas9 engineered human colon organoids. **(B)** Strategy for differential analysis of receptor-induced (extrinsic) and oncogene-induced (intrinsic) Wnt signaling. **(C)** Morphology of normal and *APC*-KO human colon organoids in control medium or 2 d after Wnt/R-spondin withdrawal. Arrowheads show differentiation of normal organoids. Scale bars are 200 µm. **(D)** qRT-PCR analysis of differentiation markers (blue) and Wnt/stem cell markers (red) in normal organoid lines 2 d after withdrawal of Wnt/R-spondin. Mean normalized expression (± SD in three technical replicates) is shown for all three organoid lines, and expression was measured twice independently. See also Fig. S1.](JEM_20180823_Fig1){#fig1}

Normal and oncogenic Wnt induce distinct transcriptional responses {#s04}
------------------------------------------------------------------

Next, we performed RNA sequencing to record the transcriptome-wide changes of the isogenic organoid lines. Principal component analysis (PCA; [Fig. 2 A](#fig2){ref-type="fig"}) showed that the variability of gene expression between donor lines largely exceeded the biological effects. However, this variability was small compared with the major transcriptional changes observed between normal organoids and paired CRC-derived organoids (Fig. S2, A and B). Thus, while a comparison of tumor and normal samples usually results in two discrete expression clusters ([@bib67]; [@bib12]), the individual variability between normal organoids exceeds the effects induced by a single oncogenic hit such as *APC*-KO. To normalize for this donor-dependent variability, we performed paired differential analysis ([Fig. 2 B](#fig2){ref-type="fig"}). This allowed us to extract 306 and 143 transcripts that were significantly up-regulated among all lines (log twofold change \>1; adjusted P value \<0.05) after Wnt-receptor stimulation (extrinsic) and *APC*-KO (intrinsic), respectively. We found few transcriptomic changes when *APC*-KO cells were treated ± Wnt/R-spondin, while simultaneous modulation of medium and genotype (combined response) caused a more pronounced biological response (833 up-regulated transcripts; Fig. S2 C). We conclude that differential analysis of isogenic organoids allows sensitive detection of single gene/pathway responses despite strong individual variation of gene expression.

![**Transcriptomic changes after extrinsic and intrinsic Wnt modulation. (A)** PCA shows that donor line--specific differences are the dominant source of gene expression variation. The 3,000 most variant genes were included for the analysis. **(B)** Differential gene expression analysis. Mean log twofold changes in *n* = 3 colon organoid lines (paired analysis). Significantly up- and down-regulated genes (±1 log twofold change; P adjust \< 0.05) are marked in red and blue, respectively. **(C and D)** GSEA using previously reported human signatures for stem cells (C) and adenomas (D). Each signature was studied in the extrinsic and intrinsic Wnt response, and NESs and *q* values are shown. See also Fig. S2.](JEM_20180823_Fig2){#fig2}

To intersect our data with previous studies of gastrointestinal Wnt/Adenoma signaling, we performed gene set enrichment analysis (GSEA). Interestingly, both of our datasets showed strong enrichment of the human colon EPHB2 stem cell signature ([@bib26]; [Fig. 2 C](#fig2){ref-type="fig"}) and of genes induced in human adenomas ([@bib45]; [Fig. 2 D](#fig2){ref-type="fig"}), an observation that was confirmed using mouse-derived stem cell and adenoma signatures ([@bib51]; [@bib41]; Fig. S2, D and E). While this overlap confirms our data and demonstrates conserved responses in mammals, it also suggests that the available signatures cannot specifically distinguish physiological from constitutive pathway activation. This is most likely due to the reported similarities between normal and cancer stem cells ([@bib69]; [@bib39]; [@bib54]).

Interestingly, we only observed limited overlap between genes that were significantly changed after Wnt-receptor stimulation and *APC* loss, some of which contained well-characterized Wnt/stem cell markers such as *ASCL2*, *AXIN2*, *LGR5*, and *SP5* ([Fig. 3 A](#fig3){ref-type="fig"}). However, on the global scale, no correlation was found between both responses (R^2^ = 0.05; [Fig. 3 B](#fig3){ref-type="fig"}). By hierarchical clustering, we could visualize two nonoverlapping classes of induced transcripts ([Fig. 3 C](#fig3){ref-type="fig"} and Table S1, A and B): a Wnt-receptor signature (146 genes) and an *APC*-KO signature (112 genes) that are expressed in a mutually exclusive manner. A third class of genes showed up-regulation in both situations, however, generally weaker in the intrinsic response, indicating that Wnt/R-spondin stimulation may not have fully saturated canonical signaling in WT organoids. By qRT-PCR, we independently validated specific markers of Wnt-receptor signaling ([Fig. 3 D](#fig3){ref-type="fig"}; *ADAMTS14*, *ASIC1, SLC2A3,* and *SMOC1*) and *APC*-KO cells (*ATOH8*, *BMX*, *CKB*, *FCGBP*, *ID3*, *MTMR11*, *RAI2*, and *VAV3*). Our profiling strategy thus allowed us to identify distinct Wnt responses in normal and adenoma cells.

![**Distinct transcriptomic signatures induced by normal and oncogenic Wnt signaling. (A)** Venn diagrams show limited overlap between significantly changed genes (± 1 log twofold change; P adjust \< 0.05) after Wnt-receptor stimulation (extrinsic) and *APC* loss-of-function (intrinsic). Genes that are part of the mouse intestinal stem cell signature are underlined. **(B)** Global correlation shows independence of intrinsic and extrinsic responses. **(C)** Unsupervised clustering identifies specific *APC*-KO and Wnt-receptor signatures. Note that a number of adenoma genes are not expressed in WT cells (black). **(D and E)** qRT-PCR validation of identified marker genes. Genes induced after Wnt-receptor stimulation (D) and *APC-*KO--induced genes (E) are shown as mean normalized expression (± SD in three technical replicates). Significant responses in all three organoid lines were determined by Student's *t* test and labeled as follows: one arrow, P \< 0.05; two arrows, P \< 0.01; three arrows, P \< 0.001; n.s., not significant. Expression was measured twice independently. See also Table S1, A and B.](JEM_20180823_Fig3){#fig3}

Next, we tested if CRC samples that are driven by alternative Wnt pathway mutations may differentially express the identified signatures. *RNF43* has been identified as a tumor suppressor in microsatellite instable CRC ([@bib19]) that causes Wnt-ligand dependent pathway activation ([@bib23]; [@bib31]). We used public TCGA (The Cancer Genome Atlas) data for differential expression analysis between colon cancers that are deficient in either *RNF43* or *APC*. Here, we could confirm that *RNF43* mutation is associated with the consensus molecular subtype 1 (CMS1), indicative of microsatellite instable CRC, whereas *APC* mutation is linked to the canonical CMS2 subtype as described before (Fig. S2 F; [@bib21]). In parallel, we could observe reciprocal and highly significant enrichment of our Wnt-receptor and *APC*-KO signatures (Fig. S2 G), supporting that also in tumors distinct responses are induced by upstream and downstream activation.

Transcriptomic signatures are preserved at different levels of intrinsic and extrinsic stimulation {#s05}
--------------------------------------------------------------------------------------------------

The divergent responses could result from quantitative differences in Wnt signaling between normal and *APC*-KO cells or involve cell differentiation in the WT. To address these questions, we performed titration experiments and first determined a Wnt concentration that causes mild reduction of growth of WT organoids rather than complete growth arrest and differentiation ([Fig. 4, A and B](#fig4){ref-type="fig"}). RNA sequencing was then performed in the absence of Wnt or in the presence of low and high concentration in WT and *APC*-KO cells ([Fig. 4 C](#fig4){ref-type="fig"}). Global analysis showed that Wnt modulation had a strong effect on WT but not on *APC*-KO cells ([Fig. 4 D](#fig4){ref-type="fig"}), consistent with our previous results (Fig. S2 C). By differential gene expression analysis, we found that maximal and submaximal stimulation induced largely overlapping responses in WT cells ([Fig. 4, E and F](#fig4){ref-type="fig"}; R^2^ = 0.46). Induction of the Wnt-receptor signature but not of the *APC*-KO signature was observed at distinct levels of stimulation ([Fig. 4 G](#fig4){ref-type="fig"}) and is thus independent from the extent of differentiation. Because the experiments were performed in the presence of a constant R-spondin concentration, R-spondin in this system does not influence the specificity of response but rather acts as a facilitator of Wnt-signaling, as suggested before ([@bib23]; [@bib31]).

![**Wnt responses after modulation of the extrinsic (A--E) and intrinsic (H--N) signaling level. (A)** Growth of normal colon organoids after titration of Wnt-conditioned medium. In each passage, the mean ATP level was measured (± SD; *n* = 3 technical replicates; donor \#3). Splitting factor was 1:5. Experiment was repeated twice with similar results. **(B)** Morphological images of organoids after culture at different Wnt concentrations. Scale bar is 1 mm. **(C)** Strategy to study maximal and submaximal Wnt stimulation. **(D)** PCA shows dose-dependent changes in WT cells and separate clustering from *APC*-KO cells (*n* = 3 technical replicates each). **(E and F)** Venn diagrams of regulated transcripts (± 1 log twofold change; P adjust \< 0.05; E) and global correlation of transcriptomic responses after maximal and submaximal Wnt stimulation (F). **(G)** GSEA shows incremental induction of the Wnt-receptor signature at distinct levels of receptor stimulation in WT cells. **(H)** Schematic representation of the APC protein and truncated variants containing three or two 20-aa repeat regions (20AAR, blue). The mutation cluster region (MCR) is indicated. **(I)** WB analysis of APC (and ACTIN for normalization) in whole-cell lysates of WT and CRISPR/Cas9 induced clonal lines (donor \#3). Black and white arrowheads show WT and truncated proteins, respectively. High frequency of a single mutant allele and absence of WT allele was measured by ICE assay. WB and ICE analyses were repeated twice independently. **(J)** Strategy to study the influence of different *APC* truncations. **(K)** PCA shows separate clustering of normal and *APC*-KO organoids (*n* = 3 each). Stimulation was performed as in [Fig. 1](#fig1){ref-type="fig"}. **(L and M)** Similar intrinsic response by *APC* variants with two and three 20AARs. Venn diagrams of regulated transcripts (L; ± 0.5 log twofold change; P adjust \< 0.05) and global correlation of changes (M). **(N)** GSEA shows similar induction of the *APC*-KO signature by both allelic variants.](JEM_20180823_Fig4){#fig4}

Next, we tested if distinct *APC* mutations influence the output of our intrinsic response. For this purpose, we generated further guide RNAs (gRNAs) targeting the mutation cluster region of the *APC* locus inducing C-terminal truncations that have been associated with distinct tumor locations and capacity of CTNNB1 down-regulation ([@bib48]; [@bib8]; see Table S2 A). *APC* alleles with zero or one remaining 20-aa repeat regions (20AARs) could not be efficiently generated, indicating that short variants may compromise growth. Besides the APC variant with two 20AARs (studied above), we could generate variants with three remaining 20AARs. As technical replicates, three hemizygous clonal lines each were derived from donor \#3 and confirmed by Sanger sequencing (interference of CRISPR edits \[ICE\] assay; [@bib24]) and WB analysis ([Fig. 4 I](#fig4){ref-type="fig"}). RNA sequencing showed global similarity among the *APC*-KO organoids but pronounced differences from normal organoids that were largely shared between both allelic variants ([Fig. 4, J--M](#fig4){ref-type="fig"}; R^2^ = 0.62). Most importantly, the *APC*-KO signature remained strongly enriched independent from the level of truncation ([Fig. 4 N](#fig4){ref-type="fig"}). In contrast, the Wnt-receptor signature was unaffected in presence of two 20AARs or was even down-regulated indicating weaker activity of the three 20AAR allele.

Specific proteomic responses induced by physiological Wnt signaling and *APC*-KO {#s06}
--------------------------------------------------------------------------------

To investigate the changes on the proteomic level, we performed a label-free quantitative mass spectrometry (MS) approach. Protein lysates were prepared from all three donors after stimulation as above (WT and two 20AAR; see [Fig. 1](#fig1){ref-type="fig"}) and in total 4,051 proteins could be identified by at least two independent peptides. For subsequent analyses, we focused on the 3,390 proteins that were detected in at least two of three organoid lines ([Fig. 5 A](#fig5){ref-type="fig"}), a large majority of which overlapped with the described characterization of normal and CRC organoids ([Fig. 5 B](#fig5){ref-type="fig"}; [@bib12]). Global data inspection again revealed a dominant line-specific variation ([Figs. 5 C](#fig5){ref-type="fig"} and S3 A). We performed pairwise differential analysis with a cutoff of P \< 0.25 to filter for proteins that show common regulation between the lines. For extrinsic and intrinsic stimulation, we identified 79 and 223 proteins, respectively, that were greater than onefold (log 2) induced ([Fig. 5 D](#fig5){ref-type="fig"}). 14 and 308 proteins were induced after *APC*-KO and combined stimulation (Fig. S3 B). GSEA revealed a highly significant enrichment of protein signatures identified in CRC organoids ([@bib12]) and in mouse Lgr5^+^ intestinal stem cells ([@bib41]; [Fig. 5, E and F](#fig5){ref-type="fig"}). However, similar to the transcriptome, the previous signatures could not discriminate between intrinsic and extrinsic activation. We observed weak correlation between transcriptomic and proteomic changes (Fig. S3 C), indicating a strong impact of posttranscriptional regulation that has been noted before in human colon samples ([@bib72]; [@bib12]). Gene ontology categories showed stronger correlation, indicating that the biological responses are preserved between RNA and protein (Fig. S3 D).

![**Proteomic changes after extrinsic and intrinsic Wnt modulation. (A)** Number of identified proteins (represented by at least two peptides) in one, two, or three organoid lines. **(B)** Venn diagram shows overlap of identified proteins (present in at least two of three lines) and the data from [@bib12]. **(C)** PCA of proteomic data. Note that the three lines cluster separately. **(D)** Pairwise differential expression analysis. Up- and down-regulated proteins (± 1 log twofold change; P \< 0.25) are marked in red and blue. **(E and F)** GSEA shows that previous proteome signatures in mouse Lgr5^+^ stem cells (E) and human CRC organoids (F) cannot discriminate between extrinsic and extrinsic Wnt responses. See also Fig. S3.](JEM_20180823_Fig5){#fig5}

Consistent with our transcriptomic analysis, we observed two largely nonoverlapping responses after Wnt-receptor stimulation and *APC*-KO ([Fig. 6, A and B](#fig6){ref-type="fig"}). Hierarchical clustering of up-regulated proteins identified mutually exclusive responses ([Fig. 6 C](#fig6){ref-type="fig"}) and we defined two protein signatures by excluding proteins that were \<0.25-fold (log 2) induced in the respective other condition. We obtained a 38-protein signature for Wnt-receptor signaling and 167 proteins upon *APC* loss (Table S1, C and D). Gene ontology analysis revealed significant association of the Wnt-receptor signature with processes such as autophagy and small GTPase signaling ("RAC signaling," "HIPPO signaling"; [Figs. 6 D](#fig6){ref-type="fig"} and S3 E). In contrast, terms related to "nuclear receptor signaling" and "chondroitin/dermatan sulfate degradation" were found in the *APC*-KO signature ([Figs. 6 D](#fig6){ref-type="fig"} and S3 F). The most strongly enriched terms were associated with DNA damage and repair such as "mismatch repair" that were shared in both signatures, indicating that both common and divergent biological programs act downstream of intrinsic and extrinsic Wnt activation. To validate the mass spectrometric data, we performed WB analysis using organoid lysates and could confirm that the proteins CEMIP, CHDH, HMGCS2, PPIPK2, SCD, SMARCA5, and SRC were indeed consistently induced upon *APC* loss ([Fig. 6 E](#fig6){ref-type="fig"}).

![**Specific protein signatures for normal and oncogenic Wnt signaling. (A)** Venn diagrams show limited overlap of proteins up- or down-regulated after Wnt-receptor (extrinsic) stimulation and *APC* loss-of-function (intrinsic). Proteins were filtered for log twofold changes ± 1 and P \< 0.25. **(B)** Global correlation shows independence of intrinsic and extrinsic responses. **(C)** Unsupervised clustering of up-regulated proteins marks distinct Wnt-receptor and *APC*-KO signatures. **(D)** Ingenuity pathway analysis. Significantly enriched gene ontology terms for Wnt-receptor and *APC*-KO protein signature are shown (red and blue bars) that were further grouped into biological categories. **(E)** WB validation of proteins. Lysates from normal and *APC*-KO organoids (*n* = 3 isogenic pairs) cultured in the presence of Wnt/R-spondin were probed. ACTIN was used for normalization. See also Fig. S3 and Table S1, C and D.](JEM_20180823_Fig6){#fig6}

New biomarkers for human adenoma cells and normal colonic stem/progenitor cells {#s07}
-------------------------------------------------------------------------------

Next, we sought to determine the representation of our protein signatures within human tissues. We took advantage of the web-based Human Protein Atlas that contains well-annotated immunohistochemistry data for normal and tumor tissues ([@bib63]). For the Wnt-receptor signature, we hypothesized a gradient-like expression in colonic crypts that is typical for Wnt/Stem cell markers ([@bib27]). After excluding markers with absent or ubiquitous expression, we could identify a specific staining pattern for 11 of 38 proteins (Table S3 A), of which nine were crypt specific. From our *APC*-KO signature, we could identify a specific staining pattern for 36 of 167 proteins (Table S3 B). Here, we found 50% with pronounced expression in tumors and normal crypts, and a further 36% that were induced in a tumor-specific manner, confirming the in vivo relevance of our data.

Because the CRC tissues contained in the Human Proteome Atlas likely have acquired numerous additional genetic hits, we collected material from early adenomas for further validation of our *APC*-KO protein signature. We included endoscopic biopsies of tubular adenomas (\<1 cm, stage 1, *n* = 9--10) and found significant enrichment of HMGCS2 ([Fig. 7 A](#fig7){ref-type="fig"}) and CEMIP ([Fig. 7 B](#fig7){ref-type="fig"}) identifying these proteins as new biomarkers for human colon adenomas. Interestingly, we noted that PPIP5K2 and AMACR (a protein induced upon extrinsic and intrinsic stimulation) displayed highly specific expression at the bottom of normal crypts in a domain similar to the known stem cell marker PTK7 ([Fig. 7 C](#fig7){ref-type="fig"}).

![**Validation of protein biomarkers for adenomas and normal stem cells. (A and B)** Adenoma-specific expression of HMGCS2 (A) and CEMIP (B). Staining was performed on *n* = 6 normal tissues and *n* = 9--10 adenomas each. Expression was scored as percentage of strong pixels per total area, and mean percentage ± SD and P values (Student's *t* test) are shown. Representative histological images of normal colon and adenoma tissue are shown next to each graph. Scale bars are 250 µm. **(C)** Immunodetection of AMACR, PPIP5K2, and the stem cell marker PTK7. Circles indicate increased expression at the bottom of colonic crypts. Scale bars are 100 µm. **(D)** FACS analysis shows increased surface expression of LRP1 and DPP4 in *APC*-KO cells (blue) compared with normal cells (red). Histogram plots in three isogenic organoid pairs that were cultured in Wnt/R-spondin containing medium. **(E)** Surface expression EPHA2 and BCAM shows reduced expression in *APC*-KO cells compared with normal cells. Experiments as in D. Stainings in A--E were independently reproduced at least twice. See also Fig. S4.](JEM_20180823_Fig7){#fig7}

In addition, we distinguished a number of surface molecules in our protein signatures that could represent powerful new tools for identification and purification of tumor cells. To explore this possibility, we performed FACS analysis using Wnt-stimulated WT and *APC-*KO organoids and found that LRP1 and DPP4 showed consistent enrichment in all three *APC-*KO lines ([Fig. 7 D](#fig7){ref-type="fig"}). Of note, these markers could discriminate normal from *APC*-KO cells better than previously reported stem cell markers EPHB2 or PTK7 in this setting (Fig. S4 A). Furthermore, we identified the cell surface proteins EPHA2 and BCAM as specifically down-regulated in *APC*-KO cells ([Fig. 7 E](#fig7){ref-type="fig"}), which allows costaining strategies to improve separation of normal and adenoma cells by flow cytometry (Fig. S4 B). Together, these results show that in vitro profiling of isogenic organoids allows identification of highly specific markers for normal and adenoma cells that are conserved in human tissues.

Opposing prognostic value of Wnt-receptor and oncogenic signatures in CRC patients {#s08}
----------------------------------------------------------------------------------

Subsequently, we sought to test if our organoid-derived signatures are associated with distinct clinical outcome in CRC. Previous transcriptome-based CRC classification has revealed active Wnt signaling in CMS2 tumors that have favorable prognosis ([@bib21]). To further differentiate this Wnt response in CRC, we performed Kaplan--Meier analysis after bifurcation according to the combined expression of the top 16 transcripts of each of our signatures (Table S1, A and B). In an age-, gender-, and stage-adjusted cohort ([GSE14333](GSE14333); 187 cases), we found that tumors characterized by high expression of the *APC*-KO signature indeed displayed significantly prolonged relapse-free survival ([Fig. 8 A](#fig8){ref-type="fig"}). In contrast, high expression of the Wnt-receptor signature predicted poor outcome ([Fig. 8 B](#fig8){ref-type="fig"}), an association that was further validated in an independent cohort ([GSE39582](GSE39582); 265 cases) for both relapse-free and overall survival (Fig. S5, A--D). We then studied published signatures for CMS2 and CMS4 tumors ([@bib35]) and found a similar, mutually exclusive association ([Fig. 8, C and D](#fig8){ref-type="fig"}; and Fig. S5, E--H). To determine the overlap between these expression-based classifications, we correlated the assignment of tumors to high and low expression groups. This analysis revealed that *APC*-KO and Wnt-receptor signatures indeed mark two sets of patients that correlate with CMS2 and CMS4 tumors ([Fig. 8 E](#fig8){ref-type="fig"}). This notion was further supported by GSEA of CMS2 and CMS4 gene signatures that displayed highly significant enrichment for the intrinsic and extrinsic responses, respectively ([Fig. 8, F and G](#fig8){ref-type="fig"}). Together, our results reveal that oncogenic and physiological Wnt responses represent two independent and opposing prognostic determinants in CRC.

![**The Wnt-receptor signature is associated with poor prognosis and overlaps with CMS4 tumors. (A--D)** Prognostic value of the *APC*-KO signature (A), the Wnt-receptor signature (B), and signatures for CMS2 (C) and CMS4 (D) tumors. Kaplan--Meier plots for relapse-free survival. For each signature, the expression cohort (GSE14333; 187 CRC cases; adjusted for age, gender, and stage) was divided into high expression (blue) and low expression (red) groups. Hazard ratios (HRs), 95% confidence intervals (CIs), and P values (log-rank test, multivariate analysis) are shown. **(E)** Pearson correlation of the individual tumor assignment to high/low expression groups in A--D. Note that CMS2/*APC*-KO signature and CMS4/Wnt-receptor signature mark two distinct groups of patients. **(F and G)** GSEA shows that CMS2 (F) and CMS4 genes (G) are strongly associated with the intrinsic and extrinsic Wnt responses in organoids, respectively. See also Fig. S5 and Table S5, A and B.](JEM_20180823_Fig8){#fig8}

Discussion {#s09}
==========

Canonical Wnt signals govern homeostasis and tumorigenesis in the gut. Here, we report the first comprehensive profiling that stratifies between Wnt responses in normal human colon and adenoma cells. The usage of isogenic organoid pairs has allowed us to normalize for donor-specific heterogeneity and to identify novel tumor and putative stem cell markers that were validated in human tissues. The described strategy permits to better differentiate the signaling activities in human CRC and link them to distinct tumor and prognostic subtypes.

Organoids provide an accessible model to dissect signals induced by the extrinsic culture environment or intrinsic activation after genetic manipulation. By comparing normal and *APC*-KO cells in the presence of Wnt-containing medium, we could normalize the physiological stimulation to obtain an oncogene-specific signature. Importantly, we report that constitutive signaling induces distinct responses compared with receptor-mediated activation. Because *APC* is lost in the majority of CRC cases, proteins identified and validated in this study could represent a set of sensitive new biomarkers (Table S4). Among this list, several proteins have enzymatic activity and could serve as therapeutic targets, which should be addressed in further studies. We suggest that a similar profiling strategy in organoids could allow identification of tumor-specific traits for other oncogenic deregulations that commonly hijack signaling pathways critical for normal cell physiology (e.g., KRAS, PI3K, NOTCH).

Another important finding is the considerable heterogeneity between normal organoids from different donors that was observed both on the transcriptome and proteome level. Previous studies have shown separate clustering of normal/adenoma and carcinoma organoids ([@bib38]; [@bib67]; [@bib12]). However, this dissimilarity might lead to an underestimation of the actual variation among normal organoids that largely exceeded the effect of Wnt stimulation or *APC* loss. Genetic differences such as expression quantitative trait loci might account for this individual variability ([@bib29]). In addition, preserved expression of gut region-specific genes might be involved ([@bib40]), although our analysis suggests to a minor extent (Fig. S2 A). Irrespective of the source of this individual variation, we conclude that bulk comparisons of tumor and normal samples have limited power to identify single gene/mutation effects. Paired analysis of engineered organoids can circumvent this problem and provide a sensitive approach to extract pathway or mutational signatures that are valid across a heterogeneous population.

We report two mutually exclusive Wnt signatures in normal and *APC*-KO cells, a distinction that was not feasible using previous signatures derived from either stem cells or primary adenomas. The most likely explanation for this lack of definition is the close association between Wnt signaling, stemness and tumorigenesis: mouse adenomatous crypts show increased β-catenin expression and consequently expand their stem cell compartment ([@bib54]). A tumor-normal comparison, thus, always includes direct and indirect effects. Likewise, differential comparison of stem cells and daughter cells detects alterations in other pathways (e.g., NOTCH), as well as the induction of differentiation genes. We aimed to normalize these confounding effects by extrinsic stimulation in order to extract the tumor-specific signaling component. The identified signatures were preserved after variation of the level of extrinsic and intrinsic stimulation ([Fig. 4](#fig4){ref-type="fig"}), indicating that the divergent responses are caused by qualitative rather than quantitative changes in Wnt signaling. In support, our signatures were differentially enriched in *RNF43* and *APC* mutant CRC (Fig. S2, G and H), which are driven by upstream and downstream pathway activity. Alternatively, ligand-dependent activation may not activate the pathway to the same extent as truncation of *APC*. Remarkably, we could observe only limited gene expression changes in *APC*-KO cells after Wnt/R-spondin stimulation (Fig. S2 C), indicating that canonical responses are saturated and that noncanonical transcriptional Wnt responses are negligible in our experimental system. In addition, the multiple layers of negative feedback regulation (e.g., by AXIN2, NKD1, RNF43, DKKs) could cause the limited response in *APC*-KO cells. On the proteomic level, the changes in *APC*-KO cells were more prominent (Fig. S3 B), indicating that posttranslational regulation, e.g., protein stabilization by Wnt-STOP signaling, could be involved ([@bib1]) that is independent of nuclear CTNNB1 function. Differential phospho-proteomic analyses could provide further mechanistic insights in future. In our analyses, we have only found a few genes that were shared between intrinsic and extrinsic responses. Interestingly, these genes were enriched for known stem cell markers such as *LGR5* and *ASCL2* ([Fig. 3 A](#fig3){ref-type="fig"}). As an in vivo correlate, we have identified adenoma-induced proteins AMACR and PPIP5K2 that also showed highly crypt bottom-specific expression in the normal colon. We conclude that stem cell markers are either characterized by a particular dose sensitivity to Wnt, or dependent on additional signals that are induced in a secondary manner both upon Wnt stimulation and in adenomas.

CRC subtypes with high Wnt-activity have been previously associated with a favorable prognosis ([@bib13]; [@bib14]; [@bib21]). It is plausible that this indicates resemblance to benign adenomas that are driven by *APC* loss and that more malignant carcinomas gradually lose Wnt profiles. In contrast, other reports have associated intestinal stem cell profiles with high risk of relapse ([@bib39]; [@bib37]; [@bib49]), where presence of Wnt-active tumor stem cells could reflect increased invasiveness ([@bib6]) and therapy resistance. These two opposing concepts emphasize a need to better understand the biology that underlies the consensus CRC subtypes. We postulate that rather than Wnt activity per se, stratification of specific downstream responses is more informative on the tumor status. Association of our *APC*-KO signature with good prognosis and the canonical subtype (CMS2) is fully consistent with the dominant role of *APC* mutations in these cases ([@bib21]). However, we found that increased receptor-mediated signaling is linked to poor prognosis in CMS4 tumors that are also rich in mesenchymal stroma. Whether this activity represents cell-autonomous expression in tumor cells, e.g., induced by the microenvironment ([@bib69]), or activation in stromal cells remains to be addressed. It appears unlikely that this expression is caused by *RNF43* deficiency, which is mainly found in microsatellite instable tumors (CMS1; [@bib19]), or the more rare R-spondin translocations that also remain dependent on external Wnt signals ([@bib60]). Yet, our findings may help to reconcile how the "stem-like" tumor subtype (described by [@bib49]) can combine malignancy with expression of specific Wnt targets. Future experiments should reveal if interference with receptor-mediated Wnt activity might allow the modulation of invasiveness.

Materials and methods {#s10}
=====================

Patient samples {#s11}
---------------

Normal human colon organoid lines were derived from nonpathological mucosa that was collected after prior written informed consent either during preemptive colonoscopy or from tumor-adjacent normal colon after tumor resection (Fig. S1 A). Additional organoid pairs from CRC and adjacent normal tissues were obtained from resected primary tumor tissues with written informed consent (Fig. S2 A). Tumor samples and patient data used in this study were provided by the University Cancer Center Frankfurt (UCT). Written informed consent was obtained from all patients, and the study was approved by the institutional review boards of the UCT and the Ethical Committee at the University Hospital Frankfurt (project-number: SGI-06-2015). Adenoma sections were collected from endoscopically resected benign colorectal polyps (T1/Dukes stage A). Only tubular adenomas and tubulovillous adenomas were included that were derived from nonhereditary cases and familial adenomatous polyposis patients. Hyperplasia and sessile (serrated) adenomas, as well as hereditary nonpolyposis CRC cases, were excluded. Normal control sections were prepared from pathologically normal tumor-adjacent mucosa (as above).

Organoid culture and transgenesis {#s12}
---------------------------------

Organoid cultures were established and maintained as described previously ([@bib52]). Human normal organoids were cultured in complete medium (advanced DMEM/F12 supplemented with 10 mM Hepes, 1× Glutamax, 1× penicillin/streptomycin, 2% B27, 1 mM nicotinamide, 12.5 mM *N*-acetylcysteine, 500 nM A83-01 \[R&D Systems\], 10 µM SB202190 \[Sigma-Aldrich\], 50% Wnt3a conditioned media \[CM\], 20% R-spondin 1 CM, 10% Noggin CM, 50 ng/ml human EGF \[Peprotech\], and 100 µg/ml Primocin \[InvivoGen\]). 10 µM of Y-27632 was added to the medium for the first 3 d after seeding. CM was prepared as described ([@bib18]), and control CM was prepared in parallel from parental L-cells and Hek293T cells. The normal phenotype of all WT organoids was confirmed by growth arrest in medium lacking Wnt3a. *APC-*KO and CRC organoids were cultured in medium lacking Wnt3a and R-spondin. For stimulations, the organoids were first seeded in regular medium for 3 d before Wnt/R-spondin was either added (+Wnt) or left out (--Wnt) for an additional 2 d, before RNA/protein collection. For normalization, the --Wnt medium contained 50% L-cell control CM and 20% Hek293T CM. For Wnt-titration experiments, cells were maintained continuously in complete medium containing 0%, 5%, 10%, 20%, 35%, or 50% of Wnt3a CM, and L-cell control CM was added for normalization. Growth was quantified at the end of each passage using the CellTiter-Glo assay (Promega) as per manufacturer's instructions, and RNA was collected at day 6 (passage 0) after seeding.

For CRISPR/Cas9 engineering, organoid lines were stably transduced with lentiCRISPR v2, a gift from Feng Zhang, Massachusetts Institute of Technology, Cambridge, MA (Addgene plasmid 52961; [@bib50]). Lentivirus production and transfection was performed as described ([@bib30]). Cas9 expression was selected by addition of 0.5--1 µg/ml puromycin to the culture medium. *APC* loss-of-function mutations were introduced by transient transfection of the plasmid gRNA_GFP-T2, a gift from George Church, Harvard Medical School, Boston, MA (Addgene plasmid 41820; [@bib36]) that contained the single-guide RNA sequences (Table S2 A). Transfection and functional selection for growth independence on Wnt/R-spondin was performed as described previously ([@bib55]). Clonal lines were expanded and confirmed by Sanger sequencing of multiple genomic amplicons (Fig. S1 B) or by ICE assay ([@bib24]). Genotyping primers for the *APC* locus were one 20AAR, 5′-GCC​ACA​GAT​ATT​CCT​TCA​TCA​CAG​A-3′ and 5′-TGG​CAA​TCG​AAC​GAC​TCT​C-3′; two 20AAR, 5′-GTT​CGA​TTG​CCA​GCT​CCG-3′ and 5′-TCA​TTT​TCC​TGA​ACT​GGA​GGC-3′; and three 20AAR, 5′-CAA​GCT​GCA​GTA​AAT​GCT​GCA-3′ and 5′-TGA​TGA​CTT​TGT​TGG​CAT​GGC-3′.

RNA collection and RT-PCR {#s13}
-------------------------

Total RNA was extracted using Macherey-Nagel NucleoSpin RNA kit according to the manufacturer's instructions. For cDNA synthesis, random hexamers and M-MLV Reverse transcription enzyme (Promega) were used. Relative gene expression was measured using Power SYBR Green PCR Master Mix (Thermo Fisher Scientific) on a StepOne Real-Time PCR instrument (Applied Biosystems) and calculated using the ΔΔCT method by normalization to HPRT expression. Data were analyzed by Student's *t* test. A list of used primers is shown in Table S2 B.

RNA sequencing and data analysis {#s14}
--------------------------------

RNA sequencing was performed using the TruSeq RNA 50 cycle kit and run on a Hiseq 2000 instrument (Illumina). Phred +33 Quality score encoding was used. 40,000,000 total reads per sample were measured. Quality of the data was monitored using FastQC Analysis. We performed quality score filtering, poly-A trimming, artifact removal, removal of N containing reads, and clearing of rRNA contamination using a pipeline provided by the HUSAR platform, German Cancer Research Center. Genomic mapping to human genome 38 was performed using TopHat2 (version 2.0.14). The number of reads per gene was determined using HTSeq count and the gencode annotations (release 24). Overlaps were handled as union. Further analysis and preparation of graphs was performed in R (versions 3.3.3 and 3.4.3) using RStudio (versions 1.0.136 and 1.1.423). We performed differential expression analysis using the DESeq2 tool (versions 1.12.4 and 1.18.1), and paired analysis was performed except in [Fig. 4](#fig4){ref-type="fig"}, where technical replicates were compared by unpaired analysis. Differential gene expression was considered significant if log twofold change was ≥1 or ≤−1 and the adjusted P value was \<0.05. Data were annotated with HGNC symbols using biomaRt (version 2.28.0). For Wnt-receptor and *APC*-KO signatures (Table S1, A and B), only transcripts were included that were changed \<0.2 log twofold in the respective other comparison. Hierarchical clustering was performed with the hclust function of the stats package (version 3.3.3) in R using Spearman correlation and average as agglomeration setting. The heatmap.2 function from gplots (version 3.0.1) was used for heat map visualization. For pairwise correlation matrices, the R dist function from the stats package (version 3.3.3) was used for distance matrix computation, and results were visualized with the help of the pheatmap package (version 1.0.8). PCAs were computed from all IDs if not specified elsewise with the prcomp function, and the pca3d package (version 0.10) was used for visualization.

Protein collection and WB analysis {#s15}
----------------------------------

Organoids were collected in cold medium and mechanically separated from the Matrigel by pipetting several times. The organoids were centrifuged at 1,200 rpm for 5 min and resuspended in cold medium, and this process was repeated at least twice to dissolve the Matrigel. Cells were lysed using modified RIPA lysis buffer (150 mM NaCl, 50 mM Tris HCl, pH 7.6, 5 mM NaF, 5 mM β-glycerophosphate, 1 mM EDTA, 1 mM Na-orthovanadate, 1% Na-deoxycholate, and 1% NP-40) containing complete protease and phosphatase inhibitors (both from Roche). Protein content was quantified using standard Bradford assay. For WB analysis, 15 µg of protein was loaded per lane and transferred to a nitrocellulose membrane and probed with the antibodies described in Table S2 C.

Liquid chomatography--MS measurements {#s16}
-------------------------------------

Protein samples were processed as described by [@bib56]. The peptides were resuspended in sample loading buffer (2% acetonitrile and 0.1% TFA) and then fractionated and analyzed by an online UltiMate 3000 RSLCnano HPLC system (Thermo Fisher Scientific) coupled online to a Q Exactive Plus mass spectrometer (Thermo Fisher Scientific). First, the peptides were desalted on a reverse phase C18 precolumn (5 × 0.3 mm diameter). After 3 min, the precolumn was switched online with the analytical column (30 cm long, 75 µm inner diameter) prepared in-house using ReproSil-Pur C18 AQ 1.9 µm reversed phase resin (Dr. Maisch GmbH). The peptides were separated with a linear gradient of 5--35% buffer (80% acetonitrile and 0.1% formic acid) at a flow rate of 300 nl/min (with back pressure of 500 bars) over 90-min gradient time. The precolumn and column temperature were set to 50°C during the chromatography. The MS data were acquired by scanning the precursors in a mass range from 350 to 1,600 m/z at a resolution of 70,000 at m/z 200. The top 20 precursor ions were chosen for MS2 by using data-dependent acquisition mode at a resolution of 17,500 at m/z 200 with maximum ion injection time of 50 ms.

MaxQuant search {#s17}
---------------

The MS raw files were processed by MaxQuant ([@bib11]; version 1.5.2.8), and MS/MS spectra were searched against UniProt human database (155,990 entries) via the Andromeda search. Mass tolerance after recalibration of precursor mass and fragment ion mass were set as 6 and 20 ppm; trypsin was selected as protease. Allowed variable modifications included protein deamidation (N) and oxidation (M). Cysteine carbamidomethylation was defined as a fixed modification. Minimal peptide length was set to 7 aa with the maximum of two enzymatic missed-cleavages. Minimum quantification radio of 2 was chosen. The false discovery rate was set to 1% for both peptide and protein identifications. MaxLFQ was chosen as algorithm for quantification.

After MaxQuant analysis, data were analyzed using Perseus software (version 1.5.5.3; MPI for Biochemistry). Reverse hits and hits identified only by side and potential contaminants were removed, and label-free quantification values from MaxQuant were log 2 transformed. Proteins were included in the analysis if they were found in at least two of three patients and if more than one peptide was found in at least one patient. Imputation of remaining missing values was performed from a normal distribution (width 0.3, down shift 1.8). We used a two-sample *t* test with a permutation-based false discovery rate of 0.05 to identify proteins with a significantly different abundance between the different comparisons. We performed paired differential analysis in Perseus and considered all proteins as regulated if the log twofold changes were ≥1 or ≤−1 and the P value was ≤0.25. Data were annotated with gene symbols using the annotation function included in Perseus. R (version 3.4.0) and RStudio (version 1.0.143) were used for data visualization. For Wnt-receptor and *APC*-KO signatures (Table S1, C and D) only proteins were included that were changed \<0.25 log twofold in the respective other comparison. Hierarchical clustering, pairwise correlation, and PCA were performed in R as described above. Identified proteins were compared with the quantified proteome data from [@bib12] (refer to supplemental material therein). For protein RNA comparison, the transcript IDs were converted in Perseus and graphs were plotted in R.

Enrichment analysis and functional annotation {#s18}
---------------------------------------------

GSEA was performed using the preranked tool (version 2.2.3; Broad Institute; [@bib62]). Data were visualized using the replotGSEA function from the Rtoolbox package. We generated ranked list files for extrinsic (WT --Wnt vs. WT +Wnt) and intrinsic (WT +Wnt vs. *APC*-KO +Wnt) regulation for the RNA sequencing and the proteome data. Additionally, we created a differential ranked list file from the intrinsic versus extrinsic RNA sequencing data by subtraction of both log twofold change values. RNA sequencing data were analyzed using the following gene sets. For the EPHB2 human intestinal stem signature, we used the supplementary table in [@bib26] and filtered all genes with an average fold change of \>2 in the category "all samples high vs. med" and which were marked as "TRUE" in the high versus med statistics. Duplicated gene names were removed, resulting in a set of 108 genes. For mouse Lgr5 intestinal stem cells, we used the mRNA signature from [@bib41] (supplemental material therein), which contains 384 genes. The human adenoma signature was derived using a publicly available dataset (Gene Expression Omnibus \[GEO\] accession no. [GSE80981](GSE80981); [@bib45]), and differential expression of control and adenoma genes was performed in GEO2R (National Center for Biotechnology Information) using the accession nos. [GSM2139717](GSM2139717), [GSM2139718](GSM2139718), and [GSM2139719](GSM2139719) (control) and [GSM2139723](GSM2139723), [GSM2139723](GSM2139723), and [GSM2139725](GSM2139725) (adenomas). The list was filtered for genes with a log twofold change of \>1, resulting in a 225-gene signature. The mouse adenoma signature was published previously ([@bib51]; also refer to MSigDB signature: SANSOM_APC_TARGETS_UP, containing 126 genes). For CMS gene sets, we classified the publicly available gene expression dataset [GSE39582](GSE39582), which was also used in the original publication from [@bib21]. Frozen robust multiarray analysis--normalized data were downloaded from the Colorectal Cancer Subtyping Consortium's Synapse platform. Gene symbols were converted to Entrez IDs using the R package biomaRt and classified by random forest analysis provided by the R package CMS classifier ([@bib21]). We identified 30 high-confidence cases for each subtype by filtering for a posterior probability value of \>50% in one CMS and \<20% in the other three CMSs (Table S5 A). For differential analysis, the identified cases were compared with all cases of the three other subtypes using the GEO2R tool. Genes with significantly induced expression (log twofold change \>1 and adjusted P \< 0.05; 341 for CMS1, 143 for CMS2, 245 for CMS3, and 681 for CMS4; see Table S5 B) were used to generate .grp files. For differential expression analysis of *APC*- and *RNF43*-deficient tumors, the mutation status was accessed from public data using cBioPortal for cancer genomics (v.1.18.0). The datasets Colorectal Adenocarcinoma (TCGA, Provisional; coadread_tcga) and Colon Adenocarcinoma (TCGA, PanCancer Atlas; coad_tcga_pan_cancer_atlas_2018) were used. Only colonic samples were included, and all 29 available samples with *RNF43* mutations (and no *APC* mutations) and 30 randomly chosen samples with *APC* mutations (and no *RNF43* or *ZNRF3* mutations) were used (see Table S5 C). HT-Seq--derived read count files were downloaded from the NIH GDC data portal, and differential analysis was performed using the DESeq2 tool as described above.

GSEA for the proteome data were performed using the following signatures: 200 proteins with log twofold change \>1 from [@bib41] (refer to supplemental material therein) and all 199 significant proteins in stem cells reported by [@bib12] (refer to supplemental material therein).

For global pairwise correlation of the GSEA and protein/RNA expression, we first performed enrichment analysis using the KEGG and REACTOME gene sets from the curated gene sets (C2) of the Molecular Signatures Database (MSigDB database v6.1; Broad Institute). All 307 normalized enrichment score (NES) values and 3,247 RNA/protein fold changes were included that were identified in both protein and RNA data, and the values were analyzed by Pearson correlation (average linkage) using the Morpheus tool (Broad Institute). Ingenuity Pathway Analysis software (version 01-07; Qiagen; default settings) was applied for gene ontology analysis of the protein signatures, and a P value of \<0.05 was considered significant.

Immunohistochemistry {#s19}
--------------------

Formalin fixed tissues were stored in 70% ethanol or directly embedded in paraffin following standard procedures. 3-µm sections were generated, and immunostaining was performed on a Leica Bond-Max, using the Bond Polymer Refine Detection System (Leica). The antibodies and staining conditions are described in Table S4 C. Following embedding, the sections were documented on a ScanScopeCS^2^ scanner equipped with a 20× objective (Olympus UPLSAPO; numerical aperture 0.75). Using Aperio eSlide Manager software (v12.3; Leica), scanned sections were analyzed, submucosal areas were excluded, and the number of positive pixels was quantified in the mucosal compartment using the pixel count algorithm. From the software output, the expression was scored as percentage of strong positive pixels per total pixels (including negative and positive pixels). Data were analyzed by Student's *t* test.

FACS analysis {#s20}
-------------

Organoids were collected in cold medium, centrifuged at 1,200 rpm for 5 min, and dissociated by incubation for 5 min with Accutase (Life Technologies; A1110501) at 37°C. Single cells were filtered through a 0.45-µm filter, centrifuged at 1,500 rpm for 5 min, and resuspended in FACS buffer (PBS, 2% FBS, and 2 mM EDTA). 1 million cells per 300 µl were incubated with antibody or isotype control for 20 min protected from light on ice. NucBlue Fixed cell (Invitrogen) was added for live cell gating. Flow cytometry was performed on BD Fortessa, and the results were analyzed using FlowJo v10 software. The list of antibodies and respective isotype controls is shown in Table S2 C.

Kaplan--Meier survival analysis {#s21}
-------------------------------

The PROGgeneV2 tool ([@bib20]) was used to analyze combined expression in the precomputed GEO datasets [GSE14333](GSE14333) and [GSE39582](GSE39582). The cohorts were adjusted for all available covariates and bifurcated based on median expression. The hazard ratios, 95% confidence intervals, and statistical analysis using log-rank test were retrieved from the program. The 16 most up-regulated transcripts were used for the Wnt-receptor and *APC*-KO signatures, respectively. Validity of the signatures was confirmed by variation of the input gene sizes to 8, 12, or 20 genes, which yielded similar results. For CMS2 and CMS4, the previously described signatures of 25 genes each were used ([@bib35]; refer to supplement therein). To link case assignment to high and low expression groups for all four signatures, Pearson correlation by average linkage was performed using the Morpheus tool (Broad Institute).

Data availability {#s22}
-----------------

The following datasets from the GEO (National Center for Biotechnology Information) were used in this study: accession nos. [GSE14333](GSE14333) ([@bib25]), [GSE39582](GSE39582) ([@bib37]), and [GSE80981](GSE80981) ([@bib45]). Gene expression datasets generated in this study are accessible under accession nos. [GSE125472](GSE125472){#dblnkce3e19fc-ee3-7a9b-cdc3-b0891e61759a} and [GSE125578](GSE125578){#dblnk16a9623b-b7d9-d132-aa20-a97ac8568b01}. The MS proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE ([@bib46]) partner repository with the dataset identifier PXD012650.

Online supplemental material {#s23}
----------------------------

Fig. S1 provides information on the CRISPR/Cas9 engineered organoids, including Sanger sequencing and WB analysis. Fig. S2 shows detailed characterization of the transcriptomic data and comparison to colon cancer samples. Fig. S3 shows detailed characterization of the proteomic data, including correlation of RNA and protein changes and gene ontology analysis. Fig. S4 shows analysis of EPHB2, PTK7, LRP1/EPHA2, and DPP4/EPHA2 surface expression in normal and *APC*-KO organoids. Fig. S5 shows relapse-free survival and overall survival for *APC*-KO and Wnt-receptor signatures in expression cohort GSE39582. Table S1 lists the protein- and RNA-based Wnt signatures. Table S2 provides all gRNAs, qPCR primers, and antibodies used. Table S3 lists the tissue expression of protein signatures in the Human Protein Atlas. Table S4 summarizes literature information of all validated proteins, and Table S5 provides information on the CMS classification and tumor subtype-specific RNA signatures.
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